SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

BACKGROUND: This multicentre, open‐label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR‐1316 plus liposomal irinotecan and 5‐fluorouracil as the first‐line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS: Eligible patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Lan, Song, Yan, Zhao, Kuaile, Liu, Ying, Fan, Qingxia, Wang, Xi, Li, Qun, Wang, Xiaopeng, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088918/
https://www.ncbi.nlm.nih.gov/pubmed/33760397
http://dx.doi.org/10.1111/1759-7714.13913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088918/
https://www.ncbi.nlm.nih.gov/pubmed/33760397
http://dx.doi.org/10.1111/1759-7714.13913

Ejemplares similares